Pharma & lifesciences

Pharma & lifesciences

Meest gelezen

A complicating factor is that a product can have a different status between European member states....
On 27 December 2016, the Belgian Law of 18 December 2016 concerning various health-related matters (“the...
While many of the details of the Regulations remain to be decided via so-called secondary legislation,...
CJEU and Belgian Supreme Court on the interaction between free movement of goods and trademark rights. On...
The Organisation for Economic Co-operation and Development (“OECD”) published on 16 January 2017 a 228-page report...
In an unprecedented move, a broad and diverse group of industry associations covering the full spectrum...
As the UK does not intend to remain in the European Economic Area (EEA) or be...
In the context of criminal proceedings concerning the potential violation of the legal requirements applicable to...
The term “industrial scale” appears twice in the draft EU Medical Devices Regulation (“MD Regulation”) in...
The EU’s regulatory framework for orphan drugs is set out in Regulation (EC) No.141/2000 (the “Orphan...
Bristows’ Biotech Review, a publication looking at many of the key developments in this area in...
In October 2014, the Nagoya Protocol entered into force. It created a new international regulatory system affecting...
Two important developments occurred in mid-November 2016 for the pharmaceutical industry in Europe: the European Commission...
On 10 November 2016, the European Union Court of Justice (ECJ) rendered a judgment regarding the...
Onlangs heeft het Hof van Justitie de Duitse wet die bepaalt dat apotheken receptplichtige geneesmiddelen voor...
As the healthcare industry continues to embrace the Internet of Things, cybersecurity may present unprecedented health...
‘In 2016 users will trust health apps more than their doctors’. So predicted Forbes Magazine in...
The decision as to which model will be adopted by the UK and the EU post-Brexit...